![Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study](https://www.researchgate.net/publication/360095072/figure/fig2/AS:1160172961579008@1653618197690/Pethidine-consumption-Percentage-of-patients-using-pethidine-A-pethidine-consumption_Q320.jpg)
Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study
![Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers | Scientific Reports Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51755-z/MediaObjects/41598_2019_51755_Fig2_HTML.png)
Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers | Scientific Reports
![Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study | SpringerLink Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10787-022-00938-8/MediaObjects/10787_2022_938_Fig4_HTML.png)
Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study | SpringerLink
![Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers - ScienceDirect Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0149291818302601-gr1.jpg)
Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers - ScienceDirect
![Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers | Scientific Reports Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-51755-z/MediaObjects/41598_2019_51755_Fig1_HTML.png)
Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers | Scientific Reports
![PDF) Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial PDF) Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial](https://i1.rgstatic.net/publication/350492306_Analgesic_efficacy_of_imrecoxib_for_postoperative_pain_following_oral_surgery_a_prospective_randomized_active-controlled_non-inferiority_trial/links/607869cf907dcf667ba11649/largepreview.png)
PDF) Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial
![(PDF) Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers (PDF) Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers](https://i1.rgstatic.net/publication/336931437_Lack_of_effect_of_Imrecoxib_an_innovative_and_moderate_COX-2_inhibitor_on_pharmacokinetics_and_pharmacodynamics_of_warfarin_in_healthy_volunteers/links/5fb65a7892851c933f3d8a9d/largepreview.png)
(PDF) Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
![Dose investigation of imrecoxib in patients with renal insufficiency based on modelling and simulation - ScienceDirect Dose investigation of imrecoxib in patients with renal insufficiency based on modelling and simulation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0928098720302384-gr1.jpg)
Dose investigation of imrecoxib in patients with renal insufficiency based on modelling and simulation - ScienceDirect
![Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study | SpringerLink Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10787-022-00938-8/MediaObjects/10787_2022_938_Fig1_HTML.png)
Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study | SpringerLink
![Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers | Scientific Reports Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-51755-z/MediaObjects/41598_2019_51755_Fig4_HTML.png)